Saratov JOURNAL of Medical and Scientific Research

Magnetic resonance imaging and biomarkers of serum and urine wile diagnostics of kidney cancer

Year: 2016, volume 12 Issue: №1 Pages: 52-56
Heading: Parmacology Article type: Original article
Authors: Nickolsky Yu.Ye., Chekhonatskaya M.L., Zakharova N.B., Popyhova E.B., Ponukalin A.N.
Organization: Saratov State Medical University

Purpose: improvement of differential diagnostics of benign and malignant renal tumors basing on complex estimation of the results of MRTand the level of such biomarkers as vascular endothelial growth factor, monocyte chemotactic protein-1 and matrix metalloproteinase-9 in blood serum and urine. Material and Methods. A total of 106 patients including the main group of 60 patients with renal cancer (RC), the group of comparison of 16 patients with benign renal tumors and the control group of 30 practically healthy persons were examined. ELISA was employed for detection of the biomarkers in blood serum and urine. The tumors were diagnosed by MRT Results. The increase of the level of the biomarkers in blood serum and urine was registered independently of the character of neoplastic process; more significant increase was observed in patients with RC, especially at the early stages of the disease. Some peculiarities of changing of the level of the biomarkers depending on the dimensions of malignant tumors were found. Conclusion. At the early stages of RC complex detection of the abovementioned biomarkers in blood serum and urine can serve an additional clinical diagnostic and prognostic criterion.

1. Matveev B.P., ed. Clinical oncourology. M.: Verdana, 2011; 934 p.
2. Alyayev Yu.G., Sinitsyn V.E., Grigor'yev N.A. Magnetic resonance tomography in urology. M.: Practical Medicine, 2005; 272 p.
3. Gorelov A.l., Soldatenkov A.V., Gorelov D.S., Selivanov A.S. Modern aspects of renal cancer prognosis. Vestnik of St Petersburg University 2008; 11 (4): 153-165
4. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005; (66): 1-9
5. FN'chenkov A.A. Therapuetic potential of angiogenesis inhibitors. Oncology 2007; (9): 321-328
6. Bergers G., Benjamin LE. Tumorogenesis and the angiogenic switch. Nat Rev Cancer 2003; (I.3): 401-410
7. Thongboonkerd V. The practical moments in uric proteomics. J Proteome Res 2007; (6): 3881-3890
8. Liu ZL, Shirakawa T, Li Y, et al. Regulation of Notch 1 and DII4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003; (23): 14-25
9. Kugler A., Hemmerlein B., Thelen P., et al. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 1998; 160 (5): 1914-1918
10. Banyra OB, Stray AA, Shulyak AV. Markers of tumor growth in renal cancer diagnostics. Experimental and Clinical Urology 2011; (4): 72-78
11. Trapeznikova M.F., Glybin P.A., Morozov А.Р., et al. Angiogenic factors in renal cell carcinoma. Oncourology 2008; (4): 82-87
12. Glybochko P.V., Durnov D.A., Ponukalin A.N. etal. Diagnostic value of metabolic oncomarker TuM2Pk and endothelial growth factor in determination of the tumor process stage in renal cancer. Meditsinskiy Vestnik Bashkortostana 2011; 6 (2): 234-239
13. Baccala AA, Zhong Н, Clift SM, et al. Serum vascular endothelial growth factor is a candidate biomarker of metastatic tumor response to ex vivo gene therapy of renal cell cancer. Urology 1998; (51): 327-332.

2016_01_052-056.pdf432.05 KB

No votes yet